California State Teachers Retirement System lessened its holdings in Quest Diagnostics Inc (NYSE:DGX) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 233,088 shares of the medical research company’s stock after selling 1,939 shares during the period. California State Teachers Retirement System owned about 0.17% of Quest Diagnostics worth $19,409,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Tekla Capital Management LLC increased its stake in Quest Diagnostics by 70.5% during the 4th quarter. Tekla Capital Management LLC now owns 66,500 shares of the medical research company’s stock worth $5,537,000 after buying an additional 27,500 shares in the last quarter. Stifel Financial Corp increased its stake in Quest Diagnostics by 467.7% during the 4th quarter. Stifel Financial Corp now owns 182,045 shares of the medical research company’s stock worth $15,014,000 after buying an additional 149,977 shares in the last quarter. Prudential PLC increased its stake in Quest Diagnostics by 159.7% during the 4th quarter. Prudential PLC now owns 23,369 shares of the medical research company’s stock worth $1,946,000 after buying an additional 14,369 shares in the last quarter. Flinton Capital Management LLC increased its stake in Quest Diagnostics by 39.6% during the 4th quarter. Flinton Capital Management LLC now owns 34,096 shares of the medical research company’s stock worth $2,839,000 after buying an additional 9,664 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Quest Diagnostics by 0.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,982,361 shares of the medical research company’s stock worth $165,058,000 after buying an additional 9,047 shares in the last quarter. Hedge funds and other institutional investors own 88.21% of the company’s stock.

In other news, Director Gail R. Wilensky sold 8,000 shares of the company’s stock in a transaction on Friday, February 22nd. The stock was sold at an average price of $87.78, for a total transaction of $702,240.00. Following the sale, the director now owns 34,604 shares of the company’s stock, valued at $3,037,539.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael E. Prevoznik sold 336 shares of the company’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $88.23, for a total value of $29,645.28. Following the sale, the senior vice president now directly owns 42,108 shares in the company, valued at approximately $3,715,188.84. The disclosure for this sale can be found here. Insiders sold 13,724 shares of company stock worth $1,199,363 over the last quarter. 1.79% of the stock is currently owned by insiders.

DGX stock opened at $88.45 on Friday. The company has a quick ratio of 0.87, a current ratio of 0.94 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $11.88 billion, a PE ratio of 14.02, a P/E/G ratio of 2.04 and a beta of 0.89. Quest Diagnostics Inc has a 1 year low of $78.95 and a 1 year high of $116.49.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, February 14th. The medical research company reported $1.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.37 by ($0.01). The company had revenue of $1.84 billion during the quarter, compared to analysts’ expectations of $1.88 billion. Quest Diagnostics had a net margin of 9.77% and a return on equity of 15.23%. Quest Diagnostics’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter last year, the company earned $1.40 earnings per share. Equities research analysts predict that Quest Diagnostics Inc will post 6.45 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 22nd. Investors of record on Monday, April 8th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date is Friday, April 5th. Quest Diagnostics’s dividend payout ratio is presently 33.60%.

DGX has been the subject of several research reports. Morgan Stanley cut their price objective on Quest Diagnostics from $120.00 to $107.00 and set an “overweight” rating for the company in a research note on Friday, November 30th. ValuEngine upgraded Quest Diagnostics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Goldman Sachs Group cut their price objective on Quest Diagnostics from $110.00 to $90.00 and set a “neutral” rating for the company in a research note on Sunday, December 9th. Zacks Investment Research upgraded Quest Diagnostics from a “sell” rating to a “hold” rating in a research note on Monday, February 18th. Finally, Credit Suisse Group reiterated a “buy” rating and set a $121.00 price objective on shares of Quest Diagnostics in a research note on Sunday, December 2nd. Two analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company’s stock. Quest Diagnostics currently has a consensus rating of “Hold” and a consensus price target of $102.82.

TRADEMARK VIOLATION WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/california-state-teachers-retirement-system-has-19-41-million-stake-in-quest-diagnostics-inc-dgx/2896620.html.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Featured Story: Bid-Ask Spread

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.